Focused ultrasound combined with radiotherapy for malignant brain tumor: a preclinical and clinical study
ConclusionReirradiation is becoming an option after disease recurrence for both primary and secondary malignant brain tumors since systemic therapy significantly prolongs survival in cancer patients. The mechanism behind the synergistic effect of RT-FUS in preclinical model needs further study. The clinical evidence from the interim analysis of an ongoing clinical trial (NCT01628406) showed a combination of RT-FUS was safe (no FUS-related adverse effect). A comprehensive analysis of radiation dosimetry and FUS energy distribution is expected after completing the final recruitment. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - December 7, 2023 Category: Cancer & Oncology Source Type: research
RFX2 promotes tumor cell stemness through epigenetic regulation of PAF1 in spinal ependymoma
ConclusionsRFX2 activates PAF1 transcription, which promotes tumor stemness of SE cells and leads to the malignant progression of SE. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - December 6, 2023 Category: Cancer & Oncology Source Type: research
Management strategies for intracranial progression in ALK-positive non-small cell lung cancer: a real-world cohort study
ConclusionThe intracranial progression-free survival showed no difference between the two strategies suggesting that both local radiotherapy and systemic therapy may be valid options. Individualized strategy, molecular analysis, and multidisciplinary conferences may all play a pivotal role in decision-making. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - December 5, 2023 Category: Cancer & Oncology Source Type: research
Treatment of very elderly glioblastoma patients ≥ 75 years of age: whom to treat
ConclusionFor very elderly patients, the natural course of disease without treatment is devastating. These patients benefit from multimodal treatment including adjuvant radiotherapy and chemotherapy. A beneficial effect of resection has not been demonstrated. Treatment options and outcomes should be thoughtfully discussed before treatment decisions are made. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - November 30, 2023 Category: Cancer & Oncology Source Type: research
Incidental meningiomas: a current and increasingly common challenge
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - November 30, 2023 Category: Cancer & Oncology Source Type: research
Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy
AbstractPurposeTo date, immunotherapeutic approaches in glioblastoma (GBM) have had limited clinical efficacy as compared to other solid tumors. Here we explore autologous cell treatments that have the potential to circumvent treatment resistance to immunotherapy for GBM.MethodsWe performed literature review and assessed clinical outcomes in phase 1 safety trials as well as phase 2 and 3 autologously-derived vaccines for the treatment of newly-diagnosed GBM. In one recent review of over 3,000 neuro-oncology phase 2 and phase 3 clinical trials, most trials were nonblinded (92%), single group (65%), nonrandomized (51%) and a...
Source: Journal of Neuro-Oncology - November 29, 2023 Category: Cancer & Oncology Source Type: research
Liquid biopsy in the setting of leptomeningeal metastases: a systematic review and meta-analysis
ConclusionCSF ctDNA is better at describing molecular landscape for LM; such an understanding may ultimately help inform patient treatment and responses to therapy. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - November 29, 2023 Category: Cancer & Oncology Source Type: research
Development of a “Geo-Tagged” tumor sample registry: intra-operative linkage of sample location to imaging
ConclusionWe are using the results of this analysis to develop a prospective sample collection protocol. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - November 28, 2023 Category: Cancer & Oncology Source Type: research
A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM)
ConclusionsAlthough Veliparib 10 mg BID administered with TMZ 75 mg/m2 for six weeks was well tolerated, when this regimen was combined with standard partial brain irradiation it was severely myelosuppressive even when the dose was reduced by 50%. This study again highlights the potential of localized cranial radiotherapy to sig nificantly increase hematologic toxicity of marginally myelosuppressive systemic therapies. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - November 28, 2023 Category: Cancer & Oncology Source Type: research
Pyruvate kinase M2 (PKM-2) expression and prognostic significance in glioblastoma patients
ConclusionPKM2 is an independent prognostic factor for survival and is associated with poor prognosis in GBM patients treated with radiotherapy. It may be a potential therapeutic target for anticancer therapy. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - November 27, 2023 Category: Cancer & Oncology Source Type: research
Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow
ConclusionA subset of primary PA cultures can be converted into long-term cell lines using SV40-TAg depending on sample intrinsic (patient age) and extrinsic workflow-related (e.g. type of medium, successful transduction) parameters. Careful monitoring of sample-intrinsic and extrinsic factors optimizes the process. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - November 24, 2023 Category: Cancer & Oncology Source Type: research
Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis
ConclusionsIntrathecal pemetrexed did not enhance OS for the entire LUAC patient with LM compared to non-intrathecal chemotherapy. However, it exhibited the potential to reduce the risk of central nervous system-related mortality and improve survival in patients with poor ECOG PS. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - November 23, 2023 Category: Cancer & Oncology Source Type: research
Treatment and survival of patients with small cell lung cancer and brain metastasis
ConclusionAlthough WBRT combined with systemic therapy offer better intracranial control in patients with SCLC and BM, this approach is not superior to the other approaches in terms of OS benefits. Emerging systemic therapies, such as immunotherapy, may be used as alternative or adjunctive treatments for specific patient populations. Further studies are warranted to refine treatment selection. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - November 20, 2023 Category: Cancer & Oncology Source Type: research
Capturing evolving definitions of 12 select rare CNS tumors: a timely report from CBTRUS and NCI-CONNECT
ConclusionsThese data provide means to measure the impact of clinical care and evaluate new therapies and the evolving histopathology definitions in rare CNS tumor types. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - November 19, 2023 Category: Cancer & Oncology Source Type: research
Particle beam radiotherapy in the treatment of WHO grade 2 and 3 meningiomas: an early experience from Shanghai Proton and Heavy Ion Center
ConclusionsTreatment-induced efficacy and toxicities to PBRT in WHO grade 2 and 3 meningiomas were both highly acceptable. Longer follow-up is needed to evaluate the long-term outcome in terms of disease control, survival, as well as potential late effects. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - November 17, 2023 Category: Cancer & Oncology Source Type: research
